|

Prevent Cardiac Surgery Associated AKI Trial

RECRUITINGPhase 2Sponsored by George Washington University
Actively Recruiting
PhasePhase 2
SponsorGeorge Washington University
Started2024-07-18
Est. completion2027-06-17
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06620523

Summary

Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Adult 18-70 years of age
* Undergoing elective CPB (Cardiopulmonary Bypass) surgery
* Baseline GFR (Glomerular Filtration Rate) ≥45 ml/min

Exclusion Criteria:

* GFR (Glomerular Filtration Rate) \<45 ml/min
* Solitary kidney
* Status post-kidney transplant
* Pregnant women
* Allergy to CoQ10
* Allergy to Glutathione
* Allergy to Cellulose

Conditions5

Coronary Artery DiseaseHeart DiseaseRenal FailureSurgerySurgery--Complications

Locations1 site

George Washington University Hospital
Washington D.C., District of Columbia, 20037
Eduard Shaykhinurov202-823-4259eshaykhinurov@mfa.gwu.edu

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.